Wells Fargo Maintains Equal-Weight on Pfizer, Lowers Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has maintained an Equal-Weight rating on Pfizer (NYSE:PFE) and lowered the price target from $39 to $35.
October 16, 2023 | 10:28 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer's price target has been lowered from $39 to $35 by Wells Fargo, while maintaining an Equal-Weight rating.
The lowering of the price target by a major financial institution like Wells Fargo could potentially lead to a decrease in Pfizer's stock price in the short term. The Equal-Weight rating suggests that the stock is expected to perform in line with the market or other stocks in its sector.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100